Cingulate Receives $4.3M Waiver from FDA Ahead of Imminent Filing for Marketing Approval of Lead ADHD Asset CTx-1301

dexmethylphenidate tri-modal release (CTx-1301) - Cingulate Therap

Jul 29, 2025